SCHEMBL2534835

SCHEMBL2534835

COc1cc(/C=C\c2ccccc2)ccc1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 2/20 0.75
TUBB1 Q9H4B7 2/20 0.75
APP P05067 5/20 0.73
MAPT P10636 1/20 0.73
TTR P02766 1/20 0.72
CYP1A2 P05177 2/20 0.71
CYP1A1 P04798 1/20 0.71
CYP1B1 Q16678 1/20 0.71
TYR P14679 1/20 0.69
ALOX5 P09917 2/20 0.68
KDM4E B2RXH2 1/20 0.66
CA12 O43570 1/20 0.66
CA1 P00915 1/20 0.66
CA2 P00918 1/20 0.66
CA3 P07451 1/20 0.66
PKM P14618 1/20 0.66
CSNK2A2 P19784 1/20 0.66
CA4 P22748 1/20 0.66
CA6 P23280 1/20 0.66
CA5A P35218 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945375 1.00 NFE2L2 (0.75) NFE2L2TUBB1APPMAPTTTR
SCHEMBL4938984 1.00 NFE2L2 (0.75) NFE2L2TUBB1APPMAPTTTR
Isoeugenol SCHEMBL2686818 0.92 TYR (0.84) NFE2L2TUBB1APPMAPTTTR
Cis/Trans-Isoeugenol SCHEMBL2686822 0.92 TYR (0.84) NFE2L2TUBB1APPMAPTTTR
SCHEMBL17732299 0.91 TTR (0.85) NFE2L2APPMAPTTTRCYP1A2
SCHEMBL671150 0.91 TTR (0.85) NFE2L2APPMAPTTTRCYP1A2
SCHEMBL30807100 0.91 TTR (0.85) NFE2L2APPMAPTTTRCYP1A2
SCHEMBL671149 0.91 TTR (0.85) NFE2L2APPMAPTTTRCYP1A2
SCHEMBL5598747 0.88 CYP2D6 (0.85) NFE2L2APPMAPTCYP1A2TYR
Ferulate SCHEMBL28581353 0.88 KDM4E (0.88) NFE2L2APPMAPTCYP1A2TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801087-B1 CIS-1,2-SUBSTITUTED STILBENE DERIVATIVES FOR TREATING AND/OR PREVENTING DIABETES INST RADIATION MED AMMS PLA (CN) 2012-08-29 EP disclosed
US-8039513-B2 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2011-10-18 US disclosed
US-8039513-B2 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2011-10-18 US disclosed
US-8039513-B2 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2011-10-18 US disclosed
US-20090161561-A1 Method and system for determining characters of channels HUAWEI TECHNOLOGIES CO., LTD 2009-06-25 US disclosed
US-20090161561-A1 Method and system for determining characters of channels HUAWEI TECHNOLOGIES CO., LTD 2009-06-25 US disclosed
US-20090161561-A1 Method and system for determining characters of channels HUAWEI TECHNOLOGIES CO., LTD 2009-06-25 US disclosed
US-20090076114-A1 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2009-03-19 US disclosed
US-20090076114-A1 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2009-03-19 US disclosed
US-20090076114-A1 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) 2009-03-19 US disclosed
EP-1801087-A1 CIS-1,2-SUBSTITUTED STILBENE DERIVATES AND THE USE THEREROF FOR MANUFACTURING MEDICAMENTS FOR TREATING MEDICAMENTS FOR TREATING AND/OR PREVENTING DIABETES Institute of Radiation Medicine, Academy of Military Medical Sciences Pla (CN) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076114-A1 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes SLC5A1, SLC5A2, SLC2A1 NFE2L2 285/4885TUBB1 1508/4885APP 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.